Fig. 1

UCMSCs with stronger Tregs-regulatory capacities have superior IPFtherapeutic effects compared to DMSCs. (a) Flowchart of UCMSCs/DMSCs treatment of BLM-induced IPF mice. (b-d)Representative immunohistochemistry images for a-SMA,Col I and quantification; scale bar, 20um. (e) TheHydroxyproline levels in the lungs. (f) The Collagen content in thelungs using Sircol® soluble collagen assay kit. (g-h) The Tregs (CD4⁺CD25⁺Foxp3⁺) levels in the blood of BLM-induced IPF mice treatedwith UC-Mix and D-Mix, determined by FCM. (i-j) The Tregs (CD4⁺CD25⁺Foxp3⁺)levels in the thoracic lymph nodes of BLM-inducedIPF mice treated with UC-Mix and D-Mix, determined by FCM. (k-l) The Tregs(CD4⁺CD25⁺Foxp3⁺) levels in the spleen ofBLM-induced IPF mice treated with UC-Mix and D-Mix, determined by FCM. (m) Flowchartof PC61 antibody administration in BLM-induced IPF micetreated with UC-Mix. PC61 mAb (anti-murine CD25 ratIgG1) was used to deplete Tregs. (n-q) The levels of Tregs in the blood and lymph nodes of mice afterblockade with the PC61 antibody, as determined by FCM. (r-s) The effectof PC61 antibody blockade on the efficacy of UC-Mix treatment in IPF mice vialung hydroxyproline and collagen levels. (UC-Mix/D-Mix: Clinical-gradeUCMSCs/DMSCs derived from three donors were mixed in a 1:1:1 ratio to eliminateindividual variations.) 3